Get the Stockscreener App
5.73
0.35%
0.02
Pre-market:
5.73
Nuvation Bio Inc stock is traded at $5.73, with a volume of 5.71M.
It is up +0.35% in the last 24 hours and down -15.24% over the past month.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
See More
Previous Close:
$5.71
Open:
$5.69
24h Volume:
5.71M
Relative Volume:
0.86
Market Cap:
$2.01B
Revenue:
$143.05M
Net Income/Loss:
$-145.99M
P/E Ratio:
-13.38
EPS:
-0.4282
Net Cash Flow:
$-134.06M
1W Performance:
-5.60%
1M Performance:
-15.24%
6M Performance:
+33.88%
1Y Performance:
+76.85%
1-Day Range:
$5.535
$5.78
1-Week Range:
$5.535
$6.26
52-Week Range:
$2.99
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
Name
Nuvation Bio Inc
Sector
Industry
Phone
332-208-6102
Address
1500 BROADWAY, NEW YORK
Compare NUVB vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
5.73 | 2.01B | 143.05M | -145.99M | -134.06M | -0.4282 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-19-25 | Initiated | B. Riley Securities | Buy |
| Sep-30-25 | Initiated | Jefferies | Buy |
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-27-24 | Upgrade | Jefferies | Hold → Buy |
| Mar-26-24 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-06-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-02-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Aug-02-22 | Downgrade | BTIG Research | Buy → Neutral |
| May-04-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-06-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-08-21 | Initiated | BMO Capital Markets | Outperform |
| Mar-08-21 | Initiated | BTIG Research | Buy |
| Mar-08-21 | Initiated | Cowen | Outperform |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Wedbush | Outperform |
View All
Nuvation Bio Inc Stock (NUVB) Latest News
NUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drug - Stocktwits
September 2026's High Insider Ownership Growth Leaders - simplywall.st
What Nuvation Bio (NUVB)'s Updated Cancer Drug Label Means For Shareholders - simplywall.st
Nuvation Bio Inc. (NUVB): Investor Outlook With A 115.82% Potential Upside - DirectorsTalk Interviews
Nuvation Bio stock gains on FDA label update for IBTROZI By Investing.com - Investing.com Australia
Why Is Nuvation Bio Stock Gaining Thursday? - Benzinga
Nuvation Bio stock gains on FDA label update for IBTROZI - Investing.com
Nuvation Bio Inc. (NUVB) latest stock news and headlines – Yahoo Finance - Yahoo Finance Singapore
Nuvation Bio stock rises on Ibtrozi label update (NUVB:NYSE) - Seeking Alpha
Nuvation Bio Inc. (NYSE:NUVB) Wins FDA OK To Add ~50-Month DOR To IBTROZI Label - TradingView
A cancer drug showed responses lasting nearly four years. FDA approved Nuvation Bio's label update. - Stock Titan
Nuvation Bio (NUVB) Reports Consistent IBTROZI Results Across ROS1 Positive NSCLC Subgroups - simplywall.st
Nuvation Bio (NUVB) Reports IBTROZI Efficacy Across ROS1 Lung Cancer Subgroups - finance.yahoo.com
Citizens maintains Nuvation Bio stock rating on competitive edge - Investing.com
Nuvation Bio presents subgroup analyses for lung cancer drug By Investing.com - Investing.com South Africa
J.P. Morgan Maintains Nuvation Bio(NUVB.US) With Buy Rating - Moomoo
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer - Investing News Network
Nuvation Bio presents subgroup analyses for lung cancer drug - Investing.com
Nuvation Bio Inc. (NYSE:NUVB) Reports Consistent IBTROZI Efficacy Across ROS1+ NSCLC Subgroups - TradingView
Nearly 9 in 10 patients responded to a lung cancer drug after chemotherapy. - Stock Titan
Nuvation Bio (NUVB) Stock Looks Stretched Despite Its 354% Three Year Run - webull.com
NUVB: IBTROZI dominates ROS1 with best-in-class efficacy, while safusidenib advances across glioma subtypes - TradingView
Nuvation Bio at 12th Annual Cantor Fitzgerald Global Healthcare Conference: pipeline gains - Investing.com
NUVB: IBTROZI’s superior efficacy and safety drive rapid market share gains, with a strong pipeline advancing - TradingView
Nuvation Bio at citigroup biopharma summit: growth rests on three pillars - Investing.com Canada
NUVB: IBTROZI and safusidenib drive growth with best-in-class efficacy and expanding global opportunities - TradingView
NUVB: IBTROZI and safusidenib drive strong growth, with major clinical and commercial milestones ahead - TradingView
Nuvation Bio (NUVB) Slips to $6.52 as Traders Weigh Support and Resistance LevelsDefined Outcome ETF - careplusvn.com
Jim Cramer sends strong 5-word message on surging biotech stock - Yahoo Finance
Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is... - Benzinga
Cramer's lightning round: Nuvation Bio 'is a pure spec' - CNBC
Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect? - Yahoo Finance
Nuvation Bio to Participate in Upcoming Investor Conferences - Investing News Network
Nuvation Bio (NUVB) Upgraded to Buy: Here's Why - Yahoo Finance
Nuvation: Why I'm Downgrading To Hold Despite Progress On NSCLC And Glioma Fronts (NUVB) - Seeking Alpha
NUVB|Nuvation Bio Inc|Price:7.100|Chg%:+0.340 - TradingKey
Nuvation Bio | 4: Statement of changes in beneficial ownership of securities-Officer Hattersley Gary - Moomoo
Nuvation Bio (NUVB) CSO sells 100K shares at $7.09 - Stock Titan
Nuvation Bio stock rises after Cantor starts at Overweight - Investing.com
Why is Nuvation Bio stock rallying today? By Investing.com - Investing.com Canada
Nuvation Bio rises as Cantor initiates at overweight - Seeking Alpha
Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating - Investing.com
Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating By Investing.com - Investing.com India
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma - Investing News Network
JPMorgan sees 100% upside in overlooked cancer drug stock - thestreet.com
FDA grants Nuvation fast-track status for safusidenib in IDH1-mutant glioma - AllSci
Nuvation Bio receives FDA fast track status for brain cancer drug - Investing.com South Africa
Market Sentiment Around Loss-Making Nuvation Bio Inc. (NYSE:NUVB) - Moomoo
One NYSEListed Biotechnology Stock at Resistance Level – NUVB - kalkine.ca
Nuvation (NUVB) Results Breakdown: EPS Comes in Above Forecast for the Current Session; Share Response - Vinanet
Nuvation Bio Inc (NUVB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Nuvation Bio Inc Stock (NUVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):